Compile Data Set for Download or QSAR
maximum 50k data
Found 80 with Last Name = 'ripka' and Initial = 'a'
TargetRhizopuspepsin(Rhizopus microsporus var. chinensis)
University Of Wisconsin-Madison

Curated by ChEMBL
LigandPNGBDBM50070005(((3R,6R,15R)-15-Hydroxymethyl-3-isopropyl-2,5-diox...)
Affinity DataKi:  1.30nMAssay Description:Compound was evaluated for potency towards nicotinic acetylcholine receptor in rat P2 brain membranes using [3H]-nicotine as a radioligandMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetRhizopuspepsin(Rhizopus microsporus var. chinensis)
University Of Wisconsin-Madison

Curated by ChEMBL
LigandPNGBDBM50070006(((Z)-(3R,6R,15R)-15-Hydroxymethyl-3-isopropyl-2,5-...)
Affinity DataKi:  336nMAssay Description:Compound was evaluated for inhibitory activity towards nicotinic acetylcholine receptor in rat P2 brain membranes using [3H]-nicotine as a radioligan...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395712(4-amino-N-((1S,3R)-3-(5-cyano-4-(1H-indol-3-yl)pyr...)
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies (Grand Island, N.Y.) using their commercially available Adapta kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM475935(US10865206, Compound 101)
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395706((+/−)-4-amino-N-(3-(5-chloro-4-(1H-indol-3-y...)
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies (Grand Island, N.Y.) using their commercially available Adapta kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395710(N-((1S,3R)-3-((5-chloro-4-(1H-indol-3-yl)pyrimidin...)
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395711( (1S,3R)—N-(4-aminophenyl)-3-(5-chloro-4-(1H-indol...)
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395711( (1S,3R)—N-(4-aminophenyl)-3-(5-chloro-4-(1H-indol...)
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies (Grand Island, N.Y.) using their commercially available Adapta kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395710(N-((1S,3R)-3-((5-chloro-4-(1H-indol-3-yl)pyrimidin...)
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies (Grand Island, N.Y.) using their commercially available Adapta kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395712(4-amino-N-((1S,3R)-3-(5-cyano-4-(1H-indol-3-yl)pyr...)
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190585(US9181219, 2-{[3-fluoro-5-(trifluoromethyl)pyridin...)
Affinity DataIC50: <200nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190585(US9181219, 2-{[3-fluoro-5-(trifluoromethyl)pyridin...)
Affinity DataIC50: <200nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190583(US9181219, 10)
Affinity DataIC50: <200nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190576(US9181219, 6)
Affinity DataIC50: <200nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190593(US9181219, 2-[(4,5-dimethylpyridin-2-yl)sulfanyl]-...)
Affinity DataIC50: <200nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190588(US9181219, 2-[(3,5-dichloropyridin-2-yl)sulfanyl]-...)
Affinity DataIC50: <200nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190588(US9181219, 2-[(3,5-dichloropyridin-2-yl)sulfanyl]-...)
Affinity DataIC50: <200nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190593(US9181219, 2-[(4,5-dimethylpyridin-2-yl)sulfanyl]-...)
Affinity DataIC50: <200nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190579(US9181219, 20)
Affinity DataIC50: <200nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190591(US9181219, 2-[(3-chloropyridin-2-yl)sulfanyl]-1-(8...)
Affinity DataIC50: <500nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190590(US9181219, 2-{[2-(8-methyl-1,2,3,4-tetrahydroquino...)
Affinity DataIC50: <500nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190586(US9181219, 2-[(5-bromopyridin-2-yl)sulfanyl]-1-(8-...)
Affinity DataIC50: <500nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190583(US9181219, 10)
Affinity DataIC50: <500nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190578(US9181219, 16)
Affinity DataIC50: <500nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190591(US9181219, 2-[(3-chloropyridin-2-yl)sulfanyl]-1-(8...)
Affinity DataIC50: <500nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190586(US9181219, 2-[(5-bromopyridin-2-yl)sulfanyl]-1-(8-...)
Affinity DataIC50: <500nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190578(US9181219, 16)
Affinity DataIC50: <500nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190576(US9181219, 6)
Affinity DataIC50: <500nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395709(4-amino-N-(5-(5-chloro-4-(1H-indol-3-yl)pyrimidin-...)
Affinity DataIC50:  550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies (Grand Island, N.Y.) using their commercially available Adapta kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395708(4-amino-N-((1S,3R)-3-(5-cyclopropyl-4-(1H-indol-3-...)
Affinity DataIC50:  550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies (Grand Island, N.Y.) using their commercially available Adapta kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395707(4-amino-N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)py...)
Affinity DataIC50:  550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies (Grand Island, N.Y.) using their commercially available Adapta kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395718(N1-(4-(((1S,3R)-3-((5-chloro-4-(1H-indol-3-yl)pyri...)
Affinity DataIC50:  550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395717(4-amino-N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)py...)
Affinity DataIC50:  550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395716(4-amino-N-(1S,3R)-3-(5-chloro-4-(4H-indol-3-yl)pyr...)
Affinity DataIC50:  550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM475948(US10865206, Compound 110)
Affinity DataIC50:  550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395714(US10308648, Compound 109 | US10865206, Compound 10...)
Affinity DataIC50:  550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395709(4-amino-N-(5-(5-chloro-4-(1H-indol-3-yl)pyrimidin-...)
Affinity DataIC50:  550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395708(4-amino-N-((1S,3R)-3-(5-cyclopropyl-4-(1H-indol-3-...)
Affinity DataIC50:  550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395707(4-amino-N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)py...)
Affinity DataIC50:  550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395718(N1-(4-(((1S,3R)-3-((5-chloro-4-(1H-indol-3-yl)pyri...)
Affinity DataIC50:  550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies (Grand Island, N.Y.) using their commercially available Adapta kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395717(4-amino-N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)py...)
Affinity DataIC50:  550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies (Grand Island, N.Y.) using their commercially available Adapta kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395714(US10308648, Compound 109 | US10865206, Compound 10...)
Affinity DataIC50:  550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies (Grand Island, N.Y.) using their commercially available Adapta kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395715((+/−)-4-amino-N-(3-(5-chloro-4-(1H-indol-3-y...)
Affinity DataIC50:  550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies (Grand Island, N.Y.) using their commercially available Adapta kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395716(4-amino-N-(1S,3R)-3-(5-chloro-4-(4H-indol-3-yl)pyr...)
Affinity DataIC50:  550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies (Grand Island, N.Y.) using their commercially available Adapta kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM475931(US10865206, Compound 100)
Affinity DataIC50: >1.00E+3nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395719(N-((1S,3R)-3-(4-(1H-indol-3-yl)pyrimidin-2-ylamino...)
Affinity DataIC50: >1.00E+3nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies (Grand Island, N.Y.) using their commercially available Adapta kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190575(US9181219, 1-(1,2,3,4-tetrahydroquinolin-1-yl)-2-{...)
Affinity DataIC50: <1.00E+3nMAssay Description:To determine whether compounds were selective for TRPV3 inhibition over inhibition of other ion channel types, the human ERG (hERG), NaV1.2, and TRPV...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM395713(4-amino-N-((1S,3R)-3-(5-chloro-4-(pyridin-3-yl)pyr...)
Affinity DataIC50: >1.00E+3nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 3(Homo sapiens (Human))
Hydra Biosciences

US Patent
LigandPNGBDBM190581(US9181219, 8)
Affinity DataIC50: <1.00E+3nMAssay Description:Phase 1: TRPV3 cells were induced 20-48 hours, removed from growth plates, and replated at low density (to attain good single-cell physical separatio...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 7(Homo sapiens (Human))
Syros Pharmaceuticals

US Patent
LigandPNGBDBM475952(US10865206, Compound 114)
Affinity DataIC50: >1.00E+3nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 80 total ) | Next | Last >>
Jump to: